Overview of Treatments Used in Transthyretin-related Hereditary Amyloidosis: a Systematic Review

Overview

Journal Eur J Hosp Pharm

Publisher BMJ Publishing Group

Specialty Pharmacy

Date 2020 Jun 27

PMID 32587078

Citations 4

Authors

Hector Cristobal Gutierrez

Ana Lara Pelayo-Negro

David Gomez Gomez

Miguel Angel Martin Vega

Marta Valero Dominguez

Affiliations

Soon will be listed here.

Abstract

Objective: To carry out a systematic review of the literature to analyse the efficacy and safety of treatments available or under investigation for amyloidosis due to mutations in the transthyretin gene (ATTR).

Methods: A bibliographic search was carried out in the following electronic databases up to September 2017: PubMed, Cochrane Library and EMBASE. The inclusion criteria were: efficacy and/or safety studies conducted in humans, studies that included treatments, including treatments in the research phase, and studies that included 10 or more patients.

Results: A total of 21 articles were included; 16 were clinical trials, eight of them (50%) phase III trials, and five were observational studies. Of the total number of studies selected, 11 were on tafamidis, four on diflunisal, two on liver transplantation, two on patisiran and two on other therapeutic alternatives. Of the 11 studies related to the drug, the pivotal trial, the results of its two extension studies and an additional post hoc analysis were selected. In addition, two phase III trials were included in specific populations, two phase II studies, one safety study and two observational studies. Regarding the four included studies related to the drug, one was the pivotal trial that gave the indication to diflunisal, another a safety summary of the pivotal trial, and the other two trials were carried out in specific populations, one in a Japanese population and another phase I trial in cardiac amyloidosis in the USA. As far as other alternatives are concerned, of the six studies included in this section, two were related to liver transplantation, two to patisiran and two to different therapeutic alternatives.

Conclusions: Sufficient evidence has not been found that demonstrates superiority among the available oral alternatives, diflunisal or tafamidis, in the treatment of ATTR. Direct comparisons between both drugs and pharmacoeconomic studies would be necessary to select the most efficient treatment.

Citing Articles

Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system.

Wu F, Zhu H, Zhang Y Sci Rep. 2024; 14(1):13691.

PMID: 38871835 PMC: 11176370. DOI: 10.1038/s41598-024-64697-y.

Chemistry, Biological Properties, and Bio-analysis of Tafamidis, a New Transthyretin Stabilizer: A Systematic Review.

Agarwal N, Sharma S, Sultan J Cardiovasc Hematol Agents Med Chem. 2023; 22(2):121-130.

PMID: 38031770 DOI: 10.2174/0118715257250153231011062855.

A molecular basis for tetramer destabilization and aggregation of transthyretin Ala97Ser.

Wang Y, Huang C, Liou G, Hsueh H, Liang C, Tseng H Protein Sci. 2023; 32(4):e4610.

PMID: 36851846 PMC: 10037696. DOI: 10.1002/pro.4610.

Treatment of acquired transthyretin amyloidosis in domino liver transplantation.

Tsamis K, Mytilinaios D, Heneghan M, Gillmore J, Gilbertson J, Giannopoulos S Clin Transplant. 2022; 37(1):e14822.

PMID: 36128766 PMC: 10078410. DOI: 10.1111/ctr.14822.

References

Ando Y, Coelho T, Berk J, Cruz M, Ericzon B, Ikeda S . Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013; 8:31. PMC: 3584981. DOI: 10.1186/1750-1172-8-31. View

Plante-Bordeneuve V, Gorram F, Salhi H, Nordine T, Ayache S, Le Corvoisier P . Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study. J Neurol. 2016; 264(2):268-276. DOI: 10.1007/s00415-016-8337-3. View

Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D . Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17(1):1-12. DOI: 10.1016/0197-2456(95)00134-4. View

Berk J, Suhr O, Obici L, Sekijima Y, Zeldenrust S, Yamashita T . Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013; 310(24):2658-67. PMC: 4139164. DOI: 10.1001/jama.2013.283815. View

Okumura K, Yamashita T, Masuda T, Misumi Y, Ueda A, Ueda M . Long-term outcome of patients with hereditary transthyretin V30M amyloidosis with polyneuropathy after liver transplantation. Amyloid. 2016; 23(1):39-45. DOI: 10.3109/13506129.2015.1123149. View

Sekijima Y, Tojo K, Morita H, Koyama J, Ikeda S . Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis. Amyloid. 2015; 22(2):79-83. DOI: 10.3109/13506129.2014.997872. View

Conceicao I, Gonzalez-Duarte A, Obici L, Schmidt H, Simoneau D, Ong M . "Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2015; 21(1):5-9. PMC: 4788142. DOI: 10.1111/jns.12153. View

Maurer M, Grogan D, Judge D, Mundayat R, Packman J, Lombardo I . Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail. 2015; 8(3):519-26. DOI: 10.1161/CIRCHEARTFAILURE.113.000890. View

Coelho T, Maia L, Silva A, Cruz M, Plante-Bordeneuve V, Lozeron P . Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012; 79(8):785-92. PMC: 4098875. DOI: 10.1212/WNL.0b013e3182661eb1. View

10.

Klamerus K, Watsky E, Moller R, Wang R, Riley S . The effect of tafamidis on the QTc interval in healthy subjects. Br J Clin Pharmacol. 2014; 79(6):918-25. PMC: 4456124. DOI: 10.1111/bcp.12561. View

11.

Cortese A, Vita G, Luigetti M, Russo M, Bisogni G, Sabatelli M . Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. J Neurol. 2016; 263(5):916-924. DOI: 10.1007/s00415-016-8064-9. View

12.

Parman Y, Adams D, Obici L, Galan L, Guergueltcheva V, Suhr O . Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP. Curr Opin Neurol. 2016; 29 Suppl 1:S3-S13. PMC: 4739317. DOI: 10.1097/WCO.0000000000000288. View

13.

Ericzon B, Wilczek H, Larsson M, Wijayatunga P, Stangou A, Pena J . Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative?. Transplantation. 2015; 99(9):1847-54. DOI: 10.1097/TP.0000000000000574. View

14.

Coelho T, Maia L, Silva A, Cruz M, Plante-Bordeneuve V, Suhr O . Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013; 260(11):2802-14. PMC: 3825212. DOI: 10.1007/s00415-013-7051-7. View

15.

Adams D, Suhr O, Hund E, Obici L, Tournev I, Campistol J . First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016; 29 Suppl 1:S14-26. PMC: 4739312. DOI: 10.1097/WCO.0000000000000289. View

16.

Benson M, Waddington-Cruz M, Berk J, Polydefkis M, Dyck P, Wang A . Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018; 379(1):22-31. DOI: 10.1056/NEJMoa1716793. View

17.

Hutton B, Catala-Lopez F, Moher D . [The PRISMA statement extension for systematic reviews incorporating network meta-analysis: PRISMA-NMA]. Med Clin (Barc). 2016; 147(6):262-6. DOI: 10.1016/j.medcli.2016.02.025. View

18.

Keohane D, Schwartz J, Gundapaneni B, Stewart M, Amass L . Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid. 2017; 24(1):30-36. DOI: 10.1080/13506129.2017.1301419. View

19.

Cruz M, Amass L, Keohane D, Schwartz J, Li H, Gundapaneni B . Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid. 2016; 23(3):178-183. PMC: 5359776. DOI: 10.1080/13506129.2016.1207163. View

20.

Suhr O, Coelho T, Buades J, Pouget J, Conceicao I, Berk J . Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J Rare Dis. 2015; 10:109. PMC: 4559363. DOI: 10.1186/s13023-015-0326-6. View